The 2014-2015 Ebola virus(EBOV)outbreak in West Africa highlighted the urgent need for specific therapeutic interventions for infected patients.The human-mouse chimeric monoclonal antibody(mAb)cocktail ZMapp,previously shown to be efficacious in EBOV(variant Kikwit)lethally infected nonhuman primates(NHPs)when administration was initiated up to 5 days,was used in some patients during the outbreak.We show that a twoantibody cocktail,MIL77E,is fully protective in NHPs when administered at 50 mg/kg 3 days after challenge with a lethal dose of EBOV variant Makona,the virus responsible for the ongoing 2014-2015 outbreak,whereas a similar formulation of ZMapp protected two of three NHPs.The chimeric MIL77E mAb cocktail is produced in engineered Chinese hamster ovary cells and is based on mAbs c13C6 and C2G4 from ZMapp.The use of only two antibodies in MIL77E opens the door to a pan-ebolavirus cocktail.